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Abstract
The infusion of donor lymphocytes transduced with a retroviral vector expressing the HSV-TK suicide gene in patients
undergoing hematopoietic stem cell transplantation for leukemia/lymphoma promotes immune reconstitution and
prevents infections and graft-versus-host disease. Analysis of the clonal dynamics of genetically modified lymphocytes in
vivo is of crucial importance to understand the potential genotoxic risk of this therapeutic approach. We used linear
amplification-mediated PCR and pyrosequencing to build a genome-wide, high-definition map of retroviral integration sites
in the genome of peripheral blood T cells from two different donors and used gene expression profiling and bioinformatics
to associate integration clusters to transcriptional activity and to genetic and epigenetic features of the T cell genome.
Comparison with matched random controls and with integrations obtained from CD34
+ hematopoietic stem/progenitor
cells showed that integration clusters occur within chromatin regions bearing epigenetic marks associated with active
promoters and regulatory elements in a cell-specific fashion. Analysis of integration sites in T cells obtained ex vivo two
months after infusion showed no evidence of integration-related clonal expansion or dominance, but rather loss of cells
harboring integration events interfering with RNA post-transcriptional processing. The study shows that high-definition
maps of retroviral integration sites are a powerful tool to analyze the fate of genetically modified T cells in patients and the
biological consequences of retroviral transduction.
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Introduction
Peripheral blood donor lymphocytes promote immune reconsti-
tution and anti-tumor activity in patients transplanted with
allogeneic hematopoietic stem cells (HSCs) for the therapy of
leukemia and lymphoma. The efficacy of donor lymphocyte
infusion (DLI) is limited, however, by the risk of graft-versus-host
disease (GvHD), a severe and often lethal complication. Expression
of a suicide transgene - the herpes simplex virus thymidine kinase
(HSV-TK) - in donor T cells allows an efficient control of GvHD by
administration of the antiviral drug ganciclovir [1,2,3,4]. DLI with
TK-transduced T cells promotes immune reconstitution and graft-
versus-leukemia (GvL) reaction, and prevents infectious complica-
tions and relapse, in patients undergoing both HLA-identical [1,3]
or HLA-haploidentical [4] HSC transplantation. In 45 patients
treatedinbothcontexts,GvHDwascontrolled in100%ofthecases,
with no loss of antiviral and anti-tumor activity [3,4]. In all cases, T
cells were transduced with SFCMM, a vector derived from the
Moloney murine leukemia retrovirus (MLV) expressing HSV-TK
and a truncated version of the low-affinity nerve growth factor
receptor (DLNGFR) as a marker for cell purification [1]. Neither
retroviral integration nor the expression of HSV-TK and DLNGFR
appearedto causeadverseeffectsinpatients treated with transduced
donor T cells [5,6,7].
The clinical use of MLV-derived vectors has raised significant
safety concerns after the occurrence of lymphoproliferative
disorders and pre-malignant clonal expansion in patients treated
for X-linked severe combined immunodeficiency [8,9] or chronic
granulomatous disease [10,11]. In all cases, the vector integrated
in the proximity of proto-oncogenes and caused their deregulation.
Similar integration events were observed in patients’ cells in other
clinical trials but did not cause adverse effects [12,13], suggesting
that other factors, such as cell context, vector design, patient’s
genetic background and conditioning regimens may contribute to
neoplastic progression. Integration of MLV and MLV-derived
vectors is non-random, with specific preferences for promoters and
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mechanisms underlying these preferences remain unknown [14].
We recently showed that MLV-derived vectors integrate prefer-
entially in hot spots around cell-specific genes, enriched in defined
subsets of transcription factor binding sites (TFBSs), and suggested
that MLV pre-integration complexes (PICs) are tethered to
transcriptionally active regulatory regions engaged by basal
components of the RNA polymerase II (Pol II) transcriptional
machinery [15,16]. On this basis, integration patterns and
frequently targeted loci are expected to be cell-specific, and
should be determined for each cell type. As a consequence, the risk
ofcausinginsertionaloncogenesismayvary whentargetingdifferent
cell types (e.g., hematopoietic progenitors vs. T lymphocytes).
Determining cell-specific integration patterns in vitro and tracking
integration events ex vivo in treated patients may help in defining
specific genotoxic risk in specific clinical contexts.
We used linear amplification-mediated PCR (LAM-PCR) and
pyrosequencing to build a genome-wide, high-definition map of
.8,000 integration sites of the SFCMM retroviral vector in the
genome of peripheral blood T cells from two different donors.
Gene expression profiling and bioinformatics were used to
associate integration clusters to transcriptional activity and to
genetic and epigenetic features of the T-cell genome. Comparison
with matched random controls and with integrations obtained
from CD34
+ multipotent hematopoietic progenitor cells (HPCs)
showed that MLV integrations cluster within chromatin regions
bearing cell-specific epigenetic marks associated with active
promoters and regulatory elements. Analysis of ,1,000 integra-
tions in T-cells obtained ex vivo two months after infusion in two
patients treated with HLA-haploidentical HSC transplantation
showed no evidence of clonal expansion but rather clonal loss of T
cells harboring certain integration events.
Results
High-definition mapping of MLV integrations in pre- and
post-infusion T cells
The study was carried out on two patients (TK38 and TK47)
enrolled in a phase-II clinical trial aimed at proving the efficacy of
the infusion of TK-transduced donor T cells in promoting
immune reconstitution and preventing GvHD after haploidentical
HSC transplantation for high-risk leukemia [4]. Peripheral blood
T cells were obtained by leukapheresis from the donors,
transduced with the SFCMM-3 retroviral vector expressing
HSV-TK and DLNGFR, and immunoselected for LNGFR
expression, as previously described [3]. TK cell infusion was
followed by a rapid (20 and 13 days after infusion in TK38 and
TK47, respectively) and sustained immune reconstitution, docu-
mented by increasing numbers of circulating T lymphocytes. Two
months after infusion, transduced T cells (,10% of the total T
cells in both patients) were retrieved from the peripheral blood
mononuclear cell fraction and immunoselected for LNGFR
expression. DNA was extracted from 10
7 cells, and vector-genome
junctions were amplified by linear amplification–mediated PCR
(LAM-PCR) [17] on DNA cleaved with three different restriction
enzymes (Tsp509I, HpyCH4IV, HinP1I). LAM-PCR products
were pyrosequenced on a 454-Roche sequencer, yielding a total of
62,181 and 33,911 raw sequence reads from pre- and post-infusion
T cells, respectively (available at the GenBank Short Read Archive
(SRA) under the accession number SRA026258). Reads contain-
ing a complete retroviral sequence up to the CA dinucleotide were
processed through an automated bioinformatic pipeline that
eliminated small and redundant sequences and mapped the valid
ones on the UCSC hg18 release of the human genome, to obtain
8,277 and 997 unique insertion sites from pre- and post-infusion T
cells, respectively (Table 1). As a control dataset, we used 40,000
random genomic sites generated in silico taking into account the
biases introduced by the LAM-PCR and pyrosequencing tech-
niques (see Methods).
For all our analyses, we arbitrarily defined ‘‘target’’ genes all
Known Genes having their transcription start site (TSS) within
50 kb from each integration/random site in either direction. In
pre-infusion T cells, the SFCMM-3 vector integrated with a
similar frequency inside and outside genes (48 vs. 52%,
respectively, UCSC Known Genes track), with a significant
over-representation of intragenic events when compared to the
random control sites (48 vs. 38.5% p,10
215, two-sample test for
equality of proportions with continuity correction). Integration
sites were annotated as TSS-proximal when mapping in the 62.5-
kb window around a TSS, intragenic when mapping within a
transcription unit .2.5 kb downstream a TSS, and intergenic in
all other cases (Figure 1A). More than 30% of the integrations
were TSS-proximal by this definition, with no significant
difference between the two patiens (Table 1). We then plotted
the distance between integration or random sites and the TSS of
their target genes, at 200 bp resolution: 16.3% of the 15,289 target
genes had an MLV insertion in the 61,700 bp interval around the
TSS, compared to a flat distribution observed for the random
control sites (Figure 1B). The distribution showed a bimodal
peak, with a drop in frequency at 6200 bp from the TSS. No
significant difference was observed between pre-infusion and post-
infusion T-cells both in the frequency of integrations within genes
(48% vs. 49%) and in the proportion of genes harboring
integrations around the TSS (16.3% vs. 14.5%, p.0.1 in all
comparisons) (Figure 1B). A significant difference was instead
observed in the orientation of the intragenic integrations between
the two datasets. In pre-infusion T cells, 51.1% of the proviruses
integrated within 4,374 genes were in forward transcriptional
orientation, a virtually random distribution (p=0.03). In post-
infusion T cells, on the contrary, the majority (62.8%) of the
proviruses integrated in 493 genes were in reverse orientation, a
significantly biased distribution (p=1.01610
215)( Table 1),
indicating a negative selection in vivo of cells carrying an intragenic,
forward-oriented MLV provirus. The bias was even more
pronounced for integrations occurring on the X chromosome,
although their number was too small to allow a statistically
significant comparison: 7 out of 8 (87.5%) X chromosome-specific,
intragenic integrations were in reverse orientation in the post-
infusion dataset vs. 28 out of 64 (44%) observed in pre-infusion
cells.
To correlate MLV integration with the expression level of the
target genes, we determined the expression profile of T cells
activated with the same procedure used for transduction (mock-
transduced) on Affymetrix HG-U133 plus 2.0 microarrays, run in
triplicate. To ensure unequivocal probe-to-gene assignment, we
re-annotated the HG-U133 plus 2.0 probe sets with custom chip
definition files (CDF) [18,19], where each of the 18,900 genes in
the microarray is associated with a single, custom probeset that
includes only probes unequivocally matching a transcript. More
than 70% of the 6,357 analyzable genes targeted by MLV
integration in pre-infusion T cells were scored as active at the time
of transduction by Affymetrix analysis, compared to 57% of the
genes hit by the random sites (p,10
215)( Figure 1C). Interest-
ingly, .90% of the 2,071 genes harboring a TSS-proximal
integration were scored as active, compared to 58% of the control
dataset, with a significant over-representation (33%) of genes in the
highest expression category (red in Figure 1C). These results
confirm the general preference of MLV for active genes, and
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active at the time of transduction. The same correlations were
observed in post-infusion T cells, with no significant overall or
patient-specific differences compared to pre-infusion T-cells
(Figure 1C).
MLV integrates in transcriptionally active chromatin
regions
To gain insight on the chromatin conformation of the genomic
regions targeted by MLV in T cells, we annotated the 8,277
integration sites in pre-infusion T cells with 41 types of histone
modifications (methylations and acetylations) or chromatin-bound
proteins mapped genome-wide in human T cells [20,21]. As a
comparison, we re-analyzed 7,782 insertions of an HIV-derived
lentiviral vector in pre-infusion T-cells [22]. The analysis was
carried out in a window of 1 kb (6500 bp) around each insertion
site, using matched random controls (see Methods for definition) as
background. The direction and strength of the correlations
between epigenetic features and retroviral integrations were
quantified using the Receiver Operation Characteristic (ROC)
method as previously described [23], allowing the associations to
be graphically expressed as heat maps. Integrations were analyzed
as a whole or broken down into TSS-proximal, intragenic and
intergenic groups. As shown in Figure 2, histone modifications
marking active transcription units and/or enhancers (all acetyla-
tions and H3K4 methylations) showed the strongest association
(red shades in the heat map) with MLV integration sites. The
association was particularly evident for, but not limited to, TSS-
proximal insertions. A similar scenario was found for the binding
of the p300 and CBP histone acetyl transferases, Pol II, the
insulator-binding protein CTCF and the H2A.Z histone variant. A
weaker enrichment of transcription-associated histone modifica-
tions was generally observed around HIV insertion sites, with the
exception of those extending throughout the body of active genes
(H4K12ac, H2BK5me1, H3K27me1, H3K36me3, and
H4K20me1). H2A.Z was under-represented around HIV inser-
tion sites compared to matched random controls. Both MLV and
HIV integrations were negatively associated (blue shades in the
heat map) with marks linked to transcriptional repression and/or
heterochromatin (H3K27 and H3K9 mono- and di-methylations).
Finally, little or no correlation with retroviral integration was
scored for histone modifications that have no evident bias towards
active or inactive genes (H3K79 methylations, H3R/H4R
methylations and H4K20me1) (Figure 2 and Supplementary
Statistical Analysis S1).
MLV integrations are clustered and target genes involved
in T-cell functions
A plot of the distance between consecutive integrations in the T-
cell genome showed that MLV integration sites were highly
clustered compared to the random integration data set, both in
pre- and post-infusion cells (Figure S1). A statistical comparison
of the distribution of MLV and random integrations indicated a
threshold of significance (p,0.01) for cluster definition of 2
integrations within 3,308 bp for pre-infusion and 27,230 bp for
post-infusion T cells, respectively (see legend of Figure S1). By
applying these thresholds, we identified 1,362 clusters containing 2
to 11 integrations in pre-infusion T cells and 102 clusters
containing 2 to 6 integrations in post-infusion T cells, targeting
2,157 and 160 genes respectively. There was no significant
difference in the relative frequency of clusters between pre- and
post-infusion T cells, as determined by sampling ten times the pre-
infusion dataset in order to compare distributions with the same
numerical complexity (two-sample Kolmogorov-Smirnov test,
p=0.66 not shown).
When analyzed at single-locus resolution, MLV integration
clusters in pre-infusion T-cells appear to co-map with promoters
and putative regulatory regions of expressed genes. Figure 3
shows three examples of such associations. A ,50-kb region
upstream of the TSS of the CD40LG gene contained 2 clusters
(black bars in Figure 3A) and a total of 9 integrations flanking
peaks of histone modifications associated with enhancer function
(H3K4me1) and upstream of the CD40LG promoter, identified by
peaks of H3K4me3, H3K9ac and Pol II. Similarly, the promoter
of the T cell-specific IL2RA gene, marked by H3K4me3 H3K9ac
and Pol II, is flanked by a cluster of 6 MLV integrations, marked
by peaks of H3K4me1 and the H2A.Z variant (Figure 3B). Three
clusters containing a total of 15 integrations were identified in less
than 40 kb in the TRAF1 locus, upstream, within and down-
stream of the transcription unit (Figure 3C). Again, the clusters
Table 1. Distribution of MLV integration sites in human T cells.
Source Integrations Intergenic TSS-proximal Intragenic
Forward
orientation*
Reverse
orientation*
Integration
clusters
Cluster
target
genes**
TK38 pre
infusion
6,044 2,031 (33.6%) 1,926 (31.9%) 2,087 (34.5%) 1,628 (50.7%) 1,584 (49.3%) 2,095
TK47 pre
infusion
2,233 783 (35.1%) 610 (27.3%) 840 (37.6%) 608 (52.3%) 554 (47.7%) 1,201
Total 8,277 2,814 (34.0%) 2,536 (30.6%) 2,927 (35.4%) 2,216 (50.9%) 2,138 (49.1%) 1,362 3,296
TK38 post
infusion
276 96 (34.8%) 71 (25.7%) 109 (39.5%) 52 (35.4%) 95 (64.6%) 69
TK47 post
infusion
721 271 (37.6%) 199 (27.6%) 251 (34.8%) 131 (37.9%) 215 (62.1%) 133
Total 997 367 (36.8%) 270 (27.1%) 360 (36.1%) 183 (37.1%) 310 (62.9%) 102 212
Distribution of MLV integration sites in the genome of pre- and post-infusion T cells from patients TK38 and TK47. Integrations were annotated for each patient as ‘TSS-
proximal’ when occurring within a distance of 62.5 kb from the TSS of at least one gene, as ‘intragenic’ when occurring into at least one gene at a distance of 2.5 kb
from the TSS, and as ‘intergenic’ in all other cases (see Figure 1).
*Number of proviruses within introns or exons in forward or reverse orientation with respect to the direction of transcription.
**Number of genes having the TSS within 650 kb from an integration cluster.
doi:10.1371/journal.pone.0015688.t001
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PLoS ONE | www.plosone.org 3 December 2010 | Volume 5 | Issue 12 | e15688Figure 1. Genomic distribution and correlation with gene expression of MLV integration sites in human T cells. (a) MLV and random
integration sites were annotated as TSS-proximal when located at 62.5 kb from a transcription start site (TSS, +1) of a Known Gene (UCSC definition),
intragenic when inside a gene at .2.5 kb from the TSS, and intergenic in any other case. Black bars represent exons of a schematic gene, arrowhead
indicate the direction of transcription. (b) Distribution of the distance of MLV vector integrations from the transcription start site (TSS) of targeted
genes in pre-infusion (red bars), and post-infusion (blue bars) T cells, at 200-bp resolution. The % of the total number of targeted genes (n) is plotted
on the Y axis. The grey area indicates the distribution of control random sites. (c) Histogram distribution of expression values from an Affymetrix
microarray (HG-U133 plus 2.0) analysis of RNA obtained from mock-transduced T lymphocytes. Affymetrix probe sets were re-annotated with custom
Retroviral Integration in T Cells
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identifying putative regulatory regions in the locus. The MLV
integration peaks appeared to be cell-specific, since no clusters and
very few, sporadic integrations were identified in the same regions
in a collection of 8,000 integrations mapped in the genome of
human cord blood CD34
+ HPCs (Cattoglio et al., submitted),
characterized by a different pattern of histone modifications
(Figure 3). Conversely, regions heavily targeted by integration
clusters in the genome of CD34
+ HPCs, such as the LMO2 locus,
contained no integration in the T-cell genome (Figure 4A). In loci
expressed in both cell types, such as RUNX1, EVI2A/B, and
ITGAL, integration clusters were localized in different regions in
HPCs (red bars) and T cells (black bars), co-mapping with cell-
specific histone modifications associated to promoters and
regulatory regions (Figure 4B–D).
Interestingly, 58% of the 102 clusters identified in post-infusion
T cells targeted genes that were targeted also in the pre-infusion
dataset (Table S1), indicating that the clustered distribution is
mostly determined by MLV integration preferences and not by
selection in vivo. Figure 5A–C shows three examples of
overlapping integration clusters in pre-infusion (red) and post-
infusion (blue) T cells in the FLJ43663, GRB7, and RHOH loci.
The only exception was the FANCD2 locus with a cluster of 4
integrations in 312 bp present only in post-infusion T cells from
patient TK38 (Figure 5D). Ten integrations were mapped at
exactly the same nucleotide in pre- and post-infusion T cells from
patient TK47 (Table S2), most likely indicating the presence of
over-represented cell clones in both samples. No such event was
observed for patient TK38, for which more integrations were
retrieved in the pre-infusion sample (6,044 vs. 2,233 in TK47) and
less in post-infusion cells (276 vs. 721). This difference may reflect
the different numbers of TK
+ cells circulating in the two patients
at the time of harvesting.
A functional classification of the genes annotated within the
integration clusters was carried out by the IngenuityH software.
Functional categories significantly over-represented in the pre-
infusion dataset included cell signaling, growth and proliferation,
development and death (red bars in Figure 6A), all above the
threshold of statistical significance (black vertical line in
Figure 6A) compared to the Ingenuity Knowledge Base
background. Over-represented disease-associated categories in-
cluded inflammatory response, immunological, hematological and
genetic disorders (Figure 6B), well related to T cell-specific
functions. All these categories were barely or not at all over-
represented in the post-infusion dataset, indicating no preferential
survival in vivo of cells harboring integrations in specific gene
categories, particularly cell growth and proliferation and cancer
(blue bars in Figure 6). To investigate the association with
oncogenic transformation more directly, we annotated all cancer-
related genes targeted by MLV integration clusters, using a
comprehensive compilation that includes proto-oncogenes and
genes associated with common insertion sites (CIS) in murine
tumors. Genes cumulatively belonging to both categories account-
ed for 11.7 and 16.0% of the genes targeted by the clusters in pre-
and post-infusion T cells respectively, a significant over-represen-
tation with respect to the frequency observed in the random
integration dataset (7.8% of 15,200 genes, p,10
24). However, the
difference between pre- and post-integration datasets was not
significant (p=0.11) and 71% of the cancer-associated genes
targeted by post-infusion clusters (in bold in Table S1) were
targeted also by pre-infusion ones, suggesting no selection in vivo
for cells harboring integrations around such genes.
An Ingenuity functional network analysis performed on the
2,157 genes targeted by pre-infusion T cells clusters displayed two
main networks, containing 30 and 31 Focus Genes in the
categories of inflammatory response (e.g., IL6, CD40LG, ITGAL)
and immunological diseases (e.g., IFNc, IFNb, IL27) respectively
(Figure 7). Only 14 and 6 of the Focus Genes in the two networks
were targeted by MLV integration in post-infusion cells (boxed in
red in Figure 7). They were not node genes of the network and
were not targeted by post-infusion integration clusters, except for
two T cell-specific genes: CD40LG, highly expressed in T cells and
crucial for their crosstalk with dendritic and B cells, and ITGAL
that plays a role in lymphocytes co-stimulatory signaling.
Discussion
Integration of MLV-derived retroviral vectors may have
significant consequences on gene expression and homeostasis of
transduced and transplanted target cells, particularly in the
hematopoietic system. The enhancer activity of the MLV LTRs
may de-regulate proto-oncogenes, and cause pre-neoplastic clonal
expansion [10,11], leukemic transformation without clonal
expansion [8,9,24], or no apparent adverse effect [13] depending
on the disease context and a number of still ill-defined factors.
Integration sites can be used as markers of clonality to study the
clonal dynamics of transduced cells in vivo, and provide important
clues to predict the potential genotoxicity of MLV integration in a
specific cell or disease context [12,22,24,25,26].
We used LAM-PCR and pyrosequencing to derive a high-
definition map of MLV integration sites in the genome of human
T cells, before and after infusion in two patients treated with DLI
after haploidentical HSC transplantation for high-risk leukemia.
The analysis of .8,000 integrations in pre-infusion T cells showed
a clustered distribution of integration sites around the TSS of
active genes and, in general, around genomic regions character-
ized by epigenetic signatures associated to active promoters and
enhancers. These included acetylations of H2A, H2B, H3 and H4,
methylations of H3 (H3K4me1, H3K4me2, H3K4me3), and
binding of the p300 and CBP histone acetil transferases, normally
associated to enhancers and promoters, Pol II, CTCF and H2AZ,
a histone variant enriched at targets of the Polycomb complex that
establishes specialized chromatin domains and plays a crucial role
in the regulation of cell commitment and differentiation [27].
Interestingly, most of these associations are statistically significant
for all integrations, whether they are TSS-proximal, intragenic or
intergenic ones, indicating that MLV PICs are attracted to regions
marked by specific epigenetic modifications independently from
their location around TSSs. Many of these modifications are
indeed specific for MLV integration, as they are either poorly
enriched (e.g., H3K9ac, H3K14ac, H3K4me3, p300 and CBP) or
under-represented (H2A.Z) around a comparable number of HIV-
derived, lentiviral vector integrations in T cells. HIV proviruses
are instead preferentially associated to histone modifications
extending throughout the body of active genes (H4K12ac,
CDF files [18] to obtain a single expression value for each gene. Expression levels were divided into four classes: absent (black portion of histogram
bars), low (below the 25
th percentile of the normalized distribution, blue), intermediate (between the 25
th and the 75
th percentile, yellow) and high
(above the 75
th percentile, red). The percentage distribution of the expression values of genes targeted by all integration/random sites (all ISs), TSS-
proximal sites (TSS-proximal ISs) and intragenic sites (intragenic ISs) are shown by the left, middle or right group of bars, respectively. The numbero f
genes (n) belonging to each category is indicated under the correspondent bar.
doi:10.1371/journal.pone.0015688.g001
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PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e15688Figure 2. Association between histone modifications and retroviral integrations in T cells. Each row in the heat map corresponds to a
different DNA-bound protein (p300, PCAF, CBP, Pol II, H2A.Z, CTCF) or histone post-translational modification (acetylation, ac, and methylation, me),
according to the ChIP-seq databases from Barski et al. [20] and Wang et al. [21]. Chromatin features were annotated in an interval of 6500 bp around
MLV and HIV vector integrations, as whole datasets or split into the three classes reported in Figure 1a. Color shades from blue to red are indicative of
the direction and the strength of the association between epigenetic features and integrations, as calculated by statistical comparison against
matched random controls using the ROC area method [23]. ROC values between 0 and 0.5 (blue shades) reflect a negative correlation compared to
random, 0.5 (grey) means no correlation, values above 0.5 (red shades) indicate a positive correlation. Results of statistical tests comparing data sets
to each other and to random can be found in the Supplementary statistical analysis S1.
doi:10.1371/journal.pone.0015688.g002
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tent with the integration preferences of lentiviral vectors [22,28].
The tendency of MLV to integrate near gene promoters has
been reported previously [14]. However, fine mapping of MLV
sites around the TSS of .2,400 genes in T cells showed a bimodal
distribution, with fewer insertions in the 2200 to +200 region,
where the general transcription factors contact the core promoter
and recruit RNA Pol II [29]. This suggests that most of the
promoters targeted by MLV PICs are engaged by the basal
transcriptional machinery, acting as a physical obstacle to
integration. Consistently, an analysis of the transcription profile
of mock-transduced T cells showed that 90% of the genes targeted
by MLV in the 62.5-kb region around the TSS are active at the
time of transduction.
Analysis of the distribution of insertion sites shows that MLV
integration is highly clustered in the T cell genome, with peaks of
integrations within apparently highly preferred regions. The
statistical definition of an integration cluster was a critical aspect
of this study. We abandoned the classical definition of ‘‘common
integration site’’ originally developed to define integration-associ-
Figure 3. MLV integration clusters in T cell-specific loci. Distribution of MLV integrations (black bars for T cells and red bars for CD34
+
hematopoietic progenitor cells), and clusters (black boxes for T cell and red boxes for CD34
+ cells), within three RefSeq gene loci (CD40LG, IL2RA,
TRAF1) specifically expressed in T cells, as displayed by the UCSC genome browser. H2A.Z, H3K4me1, H3K4me3, H3K9ac and Pol II tracks are those
determined by ChIP-seq in the genome of human CD34
+/CD133
+ HPCs [36] (in red, above the gene) and in human primary T cells [20] (in black,
below the gene). Blue boxes represent exons, arrowheads in introns indicate the direction of transcription.
doi:10.1371/journal.pone.0015688.g003
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+ HPC-specific loci. Distribution of MLV integrations and clusters within three RefSeq gene loci
expressed in both T cells and CD34
+ cells (RUNX1, EVI2A/B, ITGAL) or only in CD34
+ HPCs (LMO2), as displayed by the UCSC genome browser. See
legend of Figure 3 for explanation of symbols.
doi:10.1371/journal.pone.0015688.g004
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modeled on the size of the dataset. To define the minimal distance
between two or more integrations in a cluster, we used a procedure
that entails a variable threshold, proportional to the total number of
integration sites, allowing direct comparison between datasets of
different size. Applied to .8,000 integration sites in pre-infusion T
cells, the procedure identified .1,350 clusters, containing 2 to 11
sites and targeting 3,296 genes. Functional clustering analysis
carried out withthe Ingenuity platformindicates that genes targeted
by MLV clusters are regulated during T cell development and
differentiation, and are linked in functional networks that play
essential roles in T cell function. These include genes associated to
cancer by most classifications, suggesting that they are targeted
because of their biological rather than oncogenic function. Similar
Figure 5. Retroviral integration clusters in pre- and post-transplantation T cells. Representation of four clusters of MLV integrations in pre-
infusion (red bars) and post-infusion (blue bars) T cells, mapped by the UCSC genome browser. Location of the clusters is indicated by a vertical red
bar on the corresponding chromosome (top). Zooming-in the UCSC window, the base position feature (scale bar and nucleotide number) identifies
the genomic coordinates of the displayed region. The RefSeq genes track shows known human protein-coding transcripts taken from the NCBI RNA
reference sequences collection. Blue boxes represent exons, arrowheads indicate the direction of transcription.
doi:10.1371/journal.pone.0015688.g005
Retroviral Integration in T Cells
PLoS ONE | www.plosone.org 9 December 2010 | Volume 5 | Issue 12 | e15688correlations were already reported for genes targeted by MLV in
CD34
+ HPCs [15], indicating that MLV integration is associated to
geneexpressionprogramsinacell-specificfashion.Analysisofsingle
loci showed that genes are targeted by clusters only in the cells in
which they are expressed (e.g., IL2RA in T cells and LMO2 in
CD34
+ HPCs), where they co-map with promoters and known or
putative enhancers identified by peaks of H3K4me3, H3K4me1,
H2A.Z and Pol II. Interestingly, genes expressed in both cell types
are either targeted at the same sites (e.g., EVI2A/B) or at different,
cell-specific ones, co-localizing with cell-specific peaks of histone
modifications and Pol II binding (e.g., RUNX1). This suggests that
MLV PICs may be targeted to differentially used promoters and
enhancers, engaged bythePol IItranscriptionalmachineryina cell-
specific fashion.
An important aspect of this study was the use of integration sites
as lineage tracers to analyze the clonal dynamics of infused T cells
Figure 6. Functional classification of genes targeted by integration clusters. The figure shows those function (a) and disease (b) categories
significantly over-represented among the target genes of MLV integration clusters in pre-infusion (red bars) or post-infusion (blue bars) T cells, as
analyzed by the IngenuityH software, using the Ingenuity Pathways Knowledge Base gene population as background. P values were corrected for
multiple testing by the Bonferroni method. Statistical significance was set at a p-value of 0.01 (2 in log scale, vertical line). (n) represents the total
number of genes eligible for the analysis.
doi:10.1371/journal.pone.0015688.g006
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PLoS ONE | www.plosone.org 10 December 2010 | Volume 5 | Issue 12 | e15688Figure 7. Genes targeted by MLV integration clusters are functionally linked in gene networks. Networks originated by IngenuityH
analysis of 31 (a) and 30 (b) eligible T cell pre-infusion cluster targets. The most relevant networks, having a score of 21 (p,10
214 for all top functions
associated to the network a) and 19 (network b p,10
28) are indicated. Red boxes indicate the 14 (a) and 6 (b) Focus Genes in common with the
post-infusion dataset.
doi:10.1371/journal.pone.0015688.g007
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system in TK
+ DLI-treated patients are TK
2 cells, while TK
+ cells
are rapidly diluted in the periphery unless they expand for a
specific reason (e.g., GvHD) [3,4]. We could therefore analyze
clonal dynamics in only a minority of patients, who retained
enough TK
+ cells (.5%) in peripheral blood two months after
infusion to allow their sorting and extraction of a sufficient amount
of genomic DNA. The comparative analysis of integration sites in
pre-infusion and post-infusion T-cells showed very similar patterns
in both populations in terms of proportion of intragenic vs.
intergenic and TSS-proximal sites, distribution around the TSSs,
correlation with gene expression levels and relative abundance of
clusters. In fact, most of the clusters identified in post-infusion T
cells (102, targeting 160 genes) were observed also in pre-infusion
cells, indicating that they were generated by the MLV integration
preferences for certain genomic regions rather than by in vivo
selection. We did not observe significant patient-specific differ-
ences in any of the parameters utilized to analyze pre- vs. post-
infusion cells. Analysis of the biological functions associated to the
genes targeted by the clusters actually showed little or no over-
representations of proto-oncogenes or genes associated with signal
transduction and cell proliferation in post-infusion T cells, and no
integrations in the genes most crucial for the functional networks
that were over-represented in pre-infusion cells. These data
provide little evidence for clonal expansion or selection of cells
harboring integrations in growth-controlling or otherwise ‘‘dan-
gerous’’ genes. On the contrary, they suggest selective loss of cells
harboring integrations that may affect general or T cell-specific
functions.
The selective post-infusion loss of cells harboring proviruses in
direct transcriptional orientation within introns or exons is
particularly striking. Forward-oriented proviruses insert the
MLV splicing and polyadenylation signal in the primary
transcripts, and are likely to cause gene inactivation by aberrant
splicing and/or premature termination in a number of cases, with
consequent loss of gene function. These events are clearly
counterselected in vivo, indicating that clonal loss, rather than
dominance, is the most frequent genotoxic consequence of MLV
transduction for T cells. This hypothesis is supported by the even
stronger counterselection observed for forward-oriented proviruses
in genes active on only one allele, as those located on the X
chromosome. Orientation biases were previously observed for
endogenous retroviruses [31,32], indicating that gene-inactivating
integration events are counterselected during evolution of the host
genomes. The loss of T-cell clones observed in this study is
expected to be random and quantitatively modest, and appears to
have no consequences on the size and functionality of the donor T
cell immune repertoire, and most importantly, on the efficacy of
DLI after allogeneic HSC transplantation [3,4]. This is further
supported by the spectratype of TCR Vb families observed on
TK
+ cells sorted from the two patients. The analysis, revealed a
wide TCR repertoire, with 23 out of 24 TCR-Vb families
represented, each showing a wide, oligoclonal profile (not shown).
High-definition maps of retroviral integration sites are a
powerful tool to analyze the fate of genetically modified cells
upon administration to patients. Pre-infusion maps provide
expected targeting frequencies for gene loci and for specific
elements within each locus. Comparing these frequencies with
those observed ex vivo in follow-up studies allows to monitor any
clonal imbalance and possibly predict adverse events caused by
pre-malignant expansion of cells carrying gene deregulating
insertions. Overall, our study indicates the absence of substantial
genotoxic risks in the use of TK-modified T cells, confirming the
clinical evidence of absence of treatment-related adverse events in
over 50 patients treated over more than ten years [3,4,5,6], and
the experimental evidence of the relative resistance of T cells to
oncogene transformation compared to hematopoietic stem and
progenitor cells [33].
Materials and Methods
Patients and cells
The use of the TK DLI in the context of allo-HSC
transplantation was approved by the Italian Ministry of Health.
Orphan drug status has been granted by the European Medicine
Agency (EMA). The study, sponsored by Molmed S.p.A. (www.
molmed.com), was approved by the Institutional Review Board of
the San Raffaele Scientific Institute and informed written consent
was obtained from donors and recipients. Patients TK38 and
TK47 were treated with HLA-haploidentical HSC transplantation
for high-risk acute myeloid leukemia, in remission at time of
transplantation [4]. They received one infusion of 10
7/kg of T
cells transduced with the SFCMM-3 retroviral vector, encoding
HSV-TK and DLNGFR [1,34], as previously described [3,4].
TK-positive lymphocytes were selected after transduction to
.90% purity by immunomagnetic sorting for DLNGFR expres-
sion, and stored frozen up to the day of infusion. PBMCs were
obtained 65 (TK38) and 62 (TK47) days after infusion by Ficoll-
Hypaque gradient separation, sorted for DLNGFR expression,
and expanded in culture with OKT3, irradiated feeders and IL2.
At time of T cell harvesting, we detected 262 and 654 LNGFR
+
cells/mcl in TK38 and TK47, representing respectively 11.4%
and 30.2% of circulating CD3+ lymphocytes. Both patients
experienced moderate-grade GvHD, which was controlled by
administration of Ganciclovir. At the time of sampling, both
patients were in complete remission, free from GvHD. T cells were
harvested before ganciclovir treatment.
Sequencing, mapping and annotation of retroviral
integration sites
Genomic DNA was extracted and digested with three ‘‘four
cutter’’ enzymes: Tsp509I, HpyChIV4, HinP1. 59-LTR vector-
genome junctions were amplified by LAM-PCR as previously
described [17]. A further PCR step was performed to include
sample specific barcodes for parallel sequencing using the 454/
Roche pyrosequencing platform [35]. Sequence reads were
processed through an automated bioinformatic pipeline that
eliminated small and redundant sequences and mapped the valid
ones on the UCSC hg18 release of the human genome. Valid
reads, contained the LTR sequence up to the CA integration
dinucleotide and 20 bp or more of human genomic sequence were
used to generate a non-redundant dataset using the nrdb tool
(available at http://www.advbiocomp.com/blast.html in the AB-
BLAST software package). Non-perfectly redundant reads were
than mapped onto the human genome, requiring the alignment to
start within the first three nucleotides and to possess a minimum of
90% identity. Sequences were discarded as mapping to multiple
sites when they had more than one match on the human genome
differing in identity less than 2%. Identity for Blat was calculated
as follows: [matching nt - (mismatching nt + query gap + tile
gap)]/query size. All UCSC Known Genes having their
transcription start site (TSS) at 650 kb from an integration or
random site were annotated as targets. In case of multiple
transcript variants, we arbitrarily chose the isoform with the
nearest TSS to an integration or random site. A matched control
set of 40,000 random sites was generated in silico on the human
genome by discarding sites with the nearest Tsp509I, HpyChIV4,
or HinP1 recognition site at ,20 bp (the minimum requirement
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efficient 454 bead loading). Integration clusters were statistically
defined as described in the legend of Figure S1.
Gene expression profiling
The expression profile of T lymphocytes was determined by
microarray analysis of cells isolated from healthy donor PBMCs,
and activated for 72 hrs under the same condition used for
transduction (mock transduced). RNA was extracted from 1–
2610
6 cells, transcribed into biotinylated cRNA, hybridized to
Affymetrix HG-U133A plus 2.0 Gene Chip arrays and analyzed as
previously described [6,15]. The arrays were re-annotated using a
set of previously described custom CDFs and the corresponding
Bioconductor libraries [18,19] based on the GeneAnnot database
that compares all Affymetrix probes with transcript sequences
from publicly available cDNAs, GenBank, RefSeq and Ensembl
repositories. To correlate retroviral integration and gene activity,
average expression values from the three microarrays were divided
into four classes, i.e., absent, low (below the 25
th percentile in a
normalized distribution), intermediate (between the 25
th and the
75
th percentile) and high (above the 75
th percentile).
Functional annotation and clustering analysis
Functional annotation of genes targeted by integration clusters
were performed by the Ingenuity Pathways Analysis (IPA) tool
(Ingenuity Systems, www.ingenuity.com). Genes from the dataset
associated with biological functions and/or diseases in the
Ingenuity Pathways Knowledge Base (IPKB) were considered for
the analysis. Fischer’s exact test with Bonferroni correction for
multiple testing was used to calculate a p-value determining the
probability that each biological function and/or disease assigned
to that data set is due to chance alone. A data set containing gene
identifiers was uploaded into in the IPA application. Each gene
identifier was mapped to its corresponding gene object in the
IPKB. These genes (Focus Genes) were overlaid onto a global
molecular network developed from information contained in the
IPKB. Networks were algorithmically generated based on the
direct or indirect interaction between the sole Focus Genes. The
Functional Analysis of each network identified the biological
functions and/or diseases that were most significant to the genes in
the network (Fischer’s exact test with Bonferroni correction for
multiple testing). Cancer-associated genes were annotated using a
compiled library of proto-oncogenes and genes associated with
common insertion sites in murine tumors (http://microb230.med.
upenn.edu/protocols/cancergenes.html).
Bioinformatic analysis of associations with epigenetic
modifications
To correlate histone modifications and retroviral integration
frequency, a window of 6500 bp around each insertion site was
annotatedwith a numberofhistone methylation/acetylationsites or
bound chromatin proteins obtained from publicly available ChIP-
seq data in human primary T cells [20,21]. The distance was
calculated by subtracting the position of the integration from the
midpoint of the epigenetic feature. For comparison in the statistical
analysis, we also generated sets of matched random controls. For
this, a large library of random sites was generated, and then the
distances to restriction enzyme recognition sites scored. Each
experimental site was matched with 3 control sites that were
positioned the same number of basesfrom a restriction site as forthe
experimental site. Statistical comparisons were calculated using the
R function ‘‘ROC.strata’’ programmed by Chuck Berry [23]. The
program takes epigenetic feature counts for each insertion site and
therespective matched randomcontrols to obtaina value between 0
and 1, representing a positive or negative correlation between each
integration and that particular feature. These values are then
averaged over the entire dataset to obtain a ROC value for a given
epigenetic feature versus an integration site dataset (see Supple-
mentary statistical analysis for complete lists of ROC and P values).
Supporting Information
Statistical Analysis S1 Figure 2 presents a heat map summa-
rizing the relationship of density of sites of epigenetic modification to
sites of integration. The color code shows the frequency of each type
of modification compared to chance (i. e. random control sites). This
rar file contains an interactive version of the heat map shown in
Figure2thatallowsvisualizationoftheresultsofstatisticaltests.After
unzipping the file, open the file named main.svg in Safari. Clicking
on the heading for each row calls up statistical tests for compari-
sons to other rows. Clicking on each column calls up tests for
each column. Clicking on ‘‘compare to area=0.05’’ calls up tests
for comparison to random integration. * indicates 0.05.P.0.01;
** indicates 0.01.P.0.001; *** indicates P,0.001. A summary of
the methodsusedforstatisticaltesting canbefoundinBerryC,etal.,
PLoS Comput Biol 2: e157.
(RAR)
Figure S1 Statistical definition of retroviral integration
clusters. To establish a statistically rigorous definition of
integration cluster, we plotted the percentage distribution of the
distances (log scale on the x axis) between any MLV insertion site
(S1) and the first consecutive site (S2) in pre-infusion (red line, left
panels) and post-infusion (red line, right panels) T cells, together
with the same number of control random sites (black lines in both
panels), re-sampled 1,000 times from a collection of 40,000
random sites. Dashed vertical lines identify the threshold in the
control site distribution containing 1% or 5% of the sites,
representing the false discovery rate (FDR) for cluster definition.
With a FDR of 1%, the threshold for defining a cluster was two
integration sites in 3,308 bp for the pre-infusion and 27,230 bp for
the post-infusion dataset.
(EPS)
Table S1 Integration clusters in post-infusion T cells.
The Table show 102 integration clusters identified in post infusion
T cell. For each cluster, the table reports the number of hits
determining the cluster (cluster dimension), the source (patient),
the genomic position (chromosome, position start and end), the
target genes (gene symbol and entrez gene) and the genes in
common with clusters identified in pre-infusion T cells. Cancer-
associated genes (defined in http://microb230.med.upenn.edu/
protocols/cancergenes.html) are indicated in bold.
(DOC)
Table S2 Identical integration in pre- and post-infusion
T cells from patient TK47. The Table shows ten integrations
mapping exactly at the same nucleotide in pre- and post-infusion
T cells from patient TK47. For each integration, the table reports
the genomic position, the annotation (TSS-proximal, intragenic or
intergenic, see legend of Figure 1) and the target gene (gene
symbol and entrez gene).
(DOC)
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